IsoRay, Inc. (NYSE MKT:ISR) Q3 2020 Earnings Conference Call - Final Transcript

May 12, 2020 • 04:30 pm ET

Previous

IsoRay, Inc. (NYSE MKT:ISR) Q3 2020 Earnings Conference Call - Final Transcript

Share
Close

Loading Event

Loading Transcript

Q & A
Operator
Operator

[Operator Instructions] We'll go first to Jason Kolbert at Dawson James.

Analyst
Jason Kolbert

Well, congratulations. I know there's a lot of chaos going on across the United States. But you did put up great numbers. I think the best numbers I've seen since I'm following IsoRay. So that really is a great accomplishment. If I understand what you said Lori, the majority of those revenues were driven by prostate cancer. But you're beginning to have a glimmer of hope that GT Medical will come online as GammaTile and their salesforce engages. Is that right?

Executive
Lori Woods

Yes, that's correct Jason. And thank you, we're very excited about what we did this last quarter. To your question, yes, most of it was from prostate and then we are hopeful that GammaTile will be gaining traction and moving forward now that they've done their full market release.

Analyst
Jason Kolbert

Okay. And I just want to make sure I understood a couple of things. You mentioned that there is going to be some interruptions in COVID, both in terms of Blu Build, the device, and just a lot of other factors, but at the end of the day, procedures that were being lined up are going to be rescheduled. So, we might see a dip in April that might come back to an increase in May or June and quarter may end up being somewhat in line with kind of prior expectations. Is that fair to say?

Executive
Lori Woods

Well, I think it is fair to say that we've gotten a lot of feedback from our customers that indicates that those cases that were cancelled toward the end of March and maybe didn't get scheduled at the beginning of April. They all believe that those cases will be back and be scheduled.

And so I can't speak to exactly how next quarter will turn out. But we're very hopeful that over the next few months, we'll get them all back and taken care.

Analyst
Jason Kolbert

Sure, of course. And one last question, to -- I wanted to make sure I understood the acronym ROAPM this single bundle payment, multiple cancers that levels the playing field for brachytherapy, but what this row pan stands for?

Executive
Lori Woods

It's the radiation oncology -- Jonathan helped me out here.

Analyst
Jason Kolbert

Yes, but I did get it right, it is ROPAN, right?

Executive
Lori Woods

It's ROPAM. So, it's radiation oncology --

Executive
Jonathan Hunt

Alternative payment method.

Analyst
Jason Kolbert

Got it, alternative payment method. That's right, I just wanted to get it right so that we go in print. Listen, one last question Lori, cash is starting to get tight, do you have any thoughts about how you're going to handle the -- your cash capital needs?

Executive
Lori Woods

I'm going to turn that question over to Jonathan.

Analyst
Jason Kolbert

Okay.

Executive
Jonathan Hunt

Jason, so, we continue to believe that at our current cash levels and based on our current burn rate that we have sufficient cash to last us throughout the remainder of this calendar year. And as you probably know, we do have an ATM in place which although it's not an